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Abstract Here we show that dendritic cells accumulate the
precursor form of the leaderless secretory protein interleukin-18
(pro-interleukin-18) in the cell cytosol and in organelles co-
fractionating with endolysosomes. Upon antigen specific contact
with T lymphocytes, particulated pro-interleukin-18 decreases
rapidly, and the cytokine appears extracellularly, suggesting that
exocytosis of pro-interleukin-18-containing organelles is induced.
Exocytosis of secretory lysosomes is modulated by calcium: in
agreement with this, calcium influx results in secretion of pro-
interleukin-18. In turn, pro-interleukin-18 secretion induced by T
cells is prevented by the calcium channel blocker nifedipine. Our
results demonstrate a novel, calcium-mediated mechanism of
post-translational regulation of secretion for interleukin-18, that
allows a fast release of the cytokine. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Interleukin (IL)-18 is a cytokine with multiple biological
functions [1^3] which shares a number of features with IL-
1L. Indeed, IL-18 is expressed mainly by cells of the mono-
cyte/macrophage lineage, and possesses properties of pro-in-
£ammatory cytokines [1^3] ; similarly to IL-1L, it is synthe-
sized as a precursor protein (pro-IL-18) of 24 kDa
proteolytically processed to the 18 kDa mature form by the
IL-1L-converting enzyme (ICE) [1^3]. In addition, like IL-1,
IL-18 lacks a secretory signal sequence in spite of its extracel-
lular role, raising the question of how it can be secreted by the
producing cells [4]. In the case of IL-1L, we have partially
characterized a secretory pathway in monocytes that avoids
the classical endoplasmic reticulum (ER)^Golgi route [5], and
involves translocation of the cytosolic cytokine within a spe-
cialized subset of secretory lysosomes, whose exocytosis re-
sults in extracellular release of IL-1L [6].
Like IL-1L [22], IL-18 is produced also by dendritic cells
(DCs) [7,8], the professional antigen presenting cells [9] : chal-
lenge with antigen speci¢c T lymphocytes results in a dramatic
decrease of intracellular pro-IL-18, with detection of variable
amounts of biologically active IL-18 in cell supernatants [8].
Here we approached the problem of how pro-IL-18 synthesis,
degradation and secretion are regulated in DCs. Our data
show that pro-IL-18 is a long life intracellular protein in un-
stimulated DCs; interaction with antigen speci¢c T cells re-
sults in prompt release of the pro-IL-18 stored in secretory
organelles belonging to the endolysosomal compartment. IL-
18 secretion is modulated by calcium: the intracellular calci-
um rise that follows ionomycin treatment or opening of L-
type calcium channels induces a rapid secretion of the cyto-
kine; in turn, IL-18 secretion following the interaction with
antigen speci¢c T cells is prevented by blocking L-type calci-
um channels.
2. Materials and methods
2.1. Cells and culture conditions
DCs were obtained from adherent peripheral blood mononuclear
cells (PBMC) from healthy donors cultured 8 days in RPMI medium
supplemented with 10% fetal calf serum (both from Biochrome, Mi-
lan, Italy), 40 ng/ml recombinant granulocyte macrophage-colony
stimulating factor and 1000 U/ml of IL-4 (both from Schering-Plough
S.p.A., Milan, Italy) as described [8]. Monocytes were enriched by
adherence from PBMC and activated with 10 Wg/ml of lipopolysac-
charide (LPS) for 1 h as described [6]. Allospeci¢c T lymphocytes were
obtained by co-culturing for 1 week puri¢ed T cells with allogenic
irradiated (4000 rad) PBMC. The antigen speci¢city of the allogenic
T cells was evaluated as described [8].
DCs obtained as above were incubated in RPMI medium supple-
mented with 1% Nutridoma-HU (Boehringer, Mannheim, Germany)
for di¡erent periods of time at 37‡C in the presence or absence of
allospeci¢c T cells at a T:DC ratio of 10:1. When indicated, 100 WM
cycloheximide (Sigma-Aldrich, Milan, Italy), 1 Wg/ml of ionomycin
(Sigma-Aldrich) or 10 WM nifedipine (NFD) or 10 WM BayK 8644
(both from Calbiochem-Inalco S.p.A., Milan, Italy) or 10 nM thap-
sigargin (Sigma-Aldrich) were added to the cultures. In other experi-
ments, DCs were pretreated with 50 WM of the proteasome inhibitors
MG-132 or Z-L3VS (kind gift of Drs. M. Bogyo and H. Ploegh,
Boston, MA, USA) [10] or with the lysosomal protease inhibitors
pepstatin (10 WM) and leupeptin (100 WM) (Sigma-Aldrich) for 6 h
and co-cultured with T cells as above in the presence of the same
drugs.
2.2. Subcellular fractionation and Western blot
Aliquots of Triton X-100 (Bio-Rad, Milan, Italy) cell lysates corre-
sponding to 105 DCs (or 100 Wg of proteins) and the correspondent
trichloroacetic acid (TCA)-concentrated supernatants were solubilized
in sample bu¡er and resolved on 12% SDS^PAGE under reducing
conditions [8]. Cytosolic fraction and P1 and P2 pellets enriched in
lysosomes and endosomes, respectively, were obtained as reported [11]
with slight modi¢cations [6]. Brie£y, cells were washed, resuspended in
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homogenizing bu¡er (250 mM sucrose, 5 mM EGTA, 20 mM
HEPES-KOH, pH 7.2) at 5U107/ml and broken in a Dounce homog-
enizer. Unbroken cells, debris and nuclei were discharged by three
cycles of centrifugation at 800, 1000 and 1200Ug, and the post-nu-
clear supernatant (PNS) obtained was untreated or treated with 0.1
mg/ml of proteinase K (Sigma-Aldrich) for 30 min on ice followed by
addition of protease inhibitors, diluted 10-fold in homogenizing bu¡er
and centrifuged at 35 000Ug for 1 min. Pellet was kept as P1, P1
supernatant was centrifuged at 50 000Ug for 5 min, leading to a
second pellet (P2). The P2 supernatant from undigested PNS was
spun 30 min at 100 000Ug to eliminate all the other organelles, and
the ¢nal supernatant was concentrated by 10% TCA precipitation and
used as cytosolic fraction. When indicated, P1 and P2 fractions from
undigested PNS were pooled and treated with 0.1 mg/ml proteinase K
for 30 min on ice in the presence or absence of 0.1% Triton X-100
(Bio-Rad, Milan, Italy) before solubilization in sample bu¡er. The
enrichment in lysosomes and endosomes of P1 and P2 fractions was
evaluated by an assay for the presence of L-hexosoaminidase activity
and of cathepsin D content as described [6] (data not shown).
Western blots were performed as described [6,8]. Filters were hy-
bridized with the anti-IL-18 monoclonal antibody (mAb) (RpD Sys-
tem, Milan, Italy) or with the goat anti-human ICE p20 antibody
(Santa Cruz Biotechnology Inc., Segrate, Milan, Italy) followed by
the relevant horseradish peroxidase (HRP)-conjugated secondary anti-
body (HRP-goat anti-mouse, Dako S.p.A., Milan, Italy). When indi-
cated, ¢lms were subjected to densitometry.
3. Results
3.1. Constitutive pro-IL-18 in DCs is a long life protein
As shown in Fig. 1A, both LPS-activated monocytes and
monocyte-derived DCs synthesize considerable amounts of
the precursor form of IL-18, that migrates as a 24 kDa
band (lanes 2 and 3); the proform of the convertase ICE
(p45) is also expressed by both cell types, although DCs pro-
duce more pro-IL-18 and slightly less ICE than monocytes. In
spite of the expression of both pro-IL-18 and its convertase,
the mature form of IL-18 (lane 1 shows the migration of the
18 kDa recombinant protein) is undetectable in both DCs and
LPS-activated monocytes, at variance with cell lines co-trans-
fected with pro-IL-18 and ICE, in which intracellular process-
ing of the precursor was observed [12]. Secreted IL-18 is
barely detectable in supernatants of monocytes [13] and
DCs [8]. Kinetic analyses showed that, in DCs, pro-IL-18 is
a long life protein: indeed, treatment with the protein syn-
thesis inhibitor cycloheximide results in a slow decrease of
the pro-IL-18 content, which is s 75% of the control after
16 h with the drug (Fig. 1B). However, the antigen speci¢c
interaction of DCs with alloreactive T cells results in a reduc-
tion of intracellular pro-IL-18 of about 50% after 2 h of co-
culture, and the disappearance at 4 h (Fig. 1B). In some do-
nors (three out of 10), the reduction was even more rapid,
with lack of recovery of intracellular pro-IL-18 at 2 h ([8]
and not shown).
Fig. 1. Pro-IL-18 is a long life protein in DCs. A: Western blot
with anti-IL-18 mAb (upper panel) or anti-ICE antiserum (lower
panel) of 100 Wg of cell lysates (cl) from DCs (lane 2) or LPS-acti-
vated monocytes (MP ; lane 3). Lane 1: recombinant human IL-18
(25 ng). One representative experiment out of 12. B: Cell lysates
from DCs cultured in the absence (open circles) or presence (closed
circles) of 100 WM cycloheximide (CEX) or with alloreactive T cells
(squares) for 2, 4, 8 and 16 h. One representative experiment out of
10 is shown. The amount of intracellular IL-18 was analyzed by
Western blot and quanti¢ed by densitometry.
Fig. 2. The decrease of pro-IL-18 content upon DC^T cell interac-
tion is not due to degradation. A: 2U105 DCs were cultured for 6 h
alone (lanes 1 and 5) or with autologous activated T cells (lanes 2
and 6) or allospeci¢c T lymphocytes (lanes 3 and 7). The cell lysates
(lanes 1^3) and supernatants (lanes 5^7) from the di¡erent experi-
ments were analyzed for their content in IL-18 by Western blot as
in Fig. 1. Lanes 4 and 8: cell lysates and supernatants from 2U106
activated T cells as a control. One representative experiment out of
10 is shown. B: Cell lysates from DCs cultured for 6 h in the ab-
sence (lanes 1 and 4) or in the presence of L-Z3VS (lanes 3 and 6)
or leupeptin and pepstatin (leu+pep, lanes 2 and 5) with (lanes 4^6)
or without (lanes 1^3) alloreactive T lymphocytes (allo T) were ana-
lysed for their content in pro-IL-18 (ic pro-IL-18).
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3.2. Intracellular pro-IL-18 is not degraded upon interaction
with speci¢c T cells
The disappearance of intracellular pro-IL-18 following con-
tact with antigen speci¢c T lymphocytes is paralleled by se-
cretion of small quantities of pro-IL-18 (Fig. 2A, lanes 3 and
7) in the absence of cell damage evaluated by measurement of
the cytosolic enzyme lactate dehydrogenase in the superna-
tants (not shown). The low amounts of pro-IL-18 recovered
might be due to the fact that most of the secreted cytokine is
taken up by the responder T cells during the co-culture. Alter-
natively, pro-IL-18 may undergo degradation upon DC^T cell
interaction. Treatment with the proteasome [14] inhibitors Z-
L3VS (Fig. 2B, lanes 3 and 6) and MG-132 (not shown) for
6 h does not modify the amount of cytosolic IL-18 recovered
from either control DCs (lane 3) or DCs interacting with
alloreactive T cells (lane 6) whereas exposure to the lysosomal
protease inhibitors leupeptin and pepstatin (lanes 2 and 5)
results in only a little rescue of intracellular pro-IL-18 after
co-culture with allospeci¢c T cells, indicating that only a small
fraction of intracellular pro-IL-18 disappears due to degrada-
tion.
3.3. Pro-IL-18 in the endolysosomal fraction is the precursor of
the secreted pro-IL-18
In order to investigate the secretory mechanism of pro-IL-
18, before and after interaction with T cells, PNS from DCs
was subjected to sequential ultracentrifugations giving rise to
a soluble fraction corresponding to the cell cytosol and two
pellets, P1 and P2, enriched in lysosomes and endosomes,
respectively [6,11]. Fig. 3A shows that most of pro-IL-18 is
contained in the cytosol; however, a fraction (about 20%) is
found in P1 and P2. Particulated pro-IL-18 is protected to
protease digestion, while as expected it is degraded when the
protease treatment is carried out in the presence of detergent.
When the same subcellular fractionation experiment was per-
formed after 30 min of co-incubation with alloreactive T cells,
the amount of cytosolic pro-IL-18 was unchanged, whereas
the P1 and P2 content of pro-IL-18 was decreased (Fig. 3B).
At longer time of co-incubation, both the particulated and
cytosolic fractions resulted depleted of pro-IL-18 (not shown
and Fig. 2A).
3.4. IL-18 secretion is regulated by extracellular calcium
Cell entry of extracellular calcium mediates exocytosis of
secretory vesicles [15], including secretory lysosomes [16,17]
in several cell types. We then investigated whether modi¢ca-
tions in [Ca2]i modulate IL-18 secretion. As shown in Fig. 4,
15 min exposure to the calcium ionophore ionomycin strongly
induces secretion of pro-IL-18. Similarly, the L-type calcium
channel agonist BayK 8644 potentiates secretion, in agree-
ment with our previous observation that DCs express func-
tional L-type calcium channels [18]. In contrast, increases of
[Ca2]i following 30 min of thapsigargin treatment fail to in-
duce secretion, indicating that extracellular calcium in£ux
rather than mobilization from intracellular stores is responsi-
ble for regulated secretion. In keeping with these data, IL-18
secretion induced upon the interaction with alloreactive T
cells is prevented by pretreatment of DCs for 1 h with the
calcium channel antagonist NFD, whereas it is potentiated by
either ionomycin or BayK 8644 (Fig. 4, lanes 5^8).
4. Discussion
In this paper, we describe a novel way of control of secre-
tion for IL-18 in DCs, mediated by secretory lysosomes and
regulated by extracellular calcium in£ux. DC pro-IL-18 is a
long life protein, which in line with its lack of signal sequence
[4] accumulates in the cell cytosol : however, a consistent por-
tion co-fractionates with organelles belonging to the endoly-
sosomal compartment. We have previously proposed that in-
teraction of DCs with alloreactive T lymphocytes results in a
secretory switch of the cytokine: however, whereas the intra-
cellular pro-IL-18 content is dramatically decreased, only min-
ute amounts of pro-IL-18 are detected in the supernatants [8].
The present ¢ndings that treatment with speci¢c proteasome
or lysosomal protease inhibitors does not rescue intracellular
pro-IL-18 indicate that the rapid disappearance of the cyto-
plasmic pro-IL-18 is independent of the activation of degra-
dative processes, and support the hypothesis that the low
recovery of secreted IL-18 is due to the uptake by activated
T cells, which bear the IL-18 receptor [3]. Interestingly, anti-
Fig. 3. Emptying of particulated pro-IL-18 upon interaction with T
cells. DCs cultured for 30 min alone (A) or with alloreactive T cells
(B) were subcellular fractionated [5,10] and the P1, P2 and cytosolic
fractions were analyzed as for their content in IL-18. P1 and P2
were treated with proteinase K before solubilization in sample bu¡er
(lanes 3 and 4) or treated with proteinase K in the presence of 0.1%
Triton X-100 (PK+T-X100, lane 5).
Fig. 4. Calcium modulation of pro-IL-18 secretion. Western blot of
secreted IL-18. Lanes 1^4: DCs cultured for 30 min in the absence
(lanes 1^3) or presence of thapsigargin (lane 4) as indicated were
unstimulated (lanes 1 and 4) or stimulated for 15 min with 10 WM
BayK (lane 2) or 1 Wg/ml of ionomycin (lane 3). Lanes 5^8: DCs
cultured for 1 h in the absence (lanes 5, 6 and 8) or presence of
NFD (lane 7) were co-incubated for 6 h with alloreactive T cells
and unstimulated (lanes 5 and 7) or stimulated for the last 15 min
with 10 WM BayK (lane 6) or 1 Wg/ml ionomycin (lane 8).
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gen speci¢c T cells trigger the secretion of the pro-IL-18 con-
tained into the endolysosomal fraction, as indicated by the
decrease in the content of particulated pro-IL-18 shortly after
DC^T cell interaction. Longer interactions between DCs and
T lymphocytes lead to the emptying of the cytosol also:
whether this is due to increased translocation of cytosolic
pro-IL-18 into secretory lysosomes or to a direct secretion
across the plasma membrane remains to be established. In
any case, like for IL-1L [5], we can rule out secretion along
the ER^Golgi route, as pro-IL-18 secretion is not inhibited by
blockers of classical secretion such as brefeldin A (not shown).
The release of in£ammatory mediators as well as the secre-
tion of lysosomal hydrolases from many cell types occurs by a
regulated exocytotic process of lysosomes which behave as
secretory organelles [19]. Similarly, IL-18 could use secretory
lysosomes to reach the extracellular space: indeed, we have
recently shown that also IL-1L secretion involves exocytosis of
endolysosomal related vesicles [6]. As both IL-1L and IL-18
accumulate in the cytosol of the producing cell, their release
through secretory lysosomes would imply a translocation step
across the membrane of lysosomes or their precursor organ-
elles. A pathway of translocation for cytosolic proteins to
lysosomes under stress conditions has recently been character-
ized [20]. In that case, however, the fate of the translocated
proteins is degradation. In contrast, in Dictyostelium discoi-
deum, the transport of a leaderless adhesion protein from the
cytosol to contractile vacuoles (acidic organelles similar to
lysosomes) results in expression of this protein on the cell
surface upon exocytosis of contractile vacuoles modulated
by extracellular osmotic conditions [21]. Thus, a mechanism
of export of leaderless secretory proteins that uses intracellu-
lar acidic vesicles as a vehicle to the extracellular space might
have been conserved along evolution. In monocytes, exocyto-
sis of IL-1L-containing endolysosomes resulting in IL-1L se-
cretion is triggered by extracellular ATP [6]. In contrast, se-
cretion of pro-IL-18 by DCs is una¡ected by ATP, but is
induced by calcium in£ux. This is in agreement with a number
of reports showing a calcium-regulated exocytosis of secretory
lysosomes in various cell types [16,17]. Whereas calcium ion-
ophores inducing extracellular calcium entry promote pro-IL-
18 secretion, mobilization of calcium from intracellular stores
does not. Moreover, treatment of DCs with BayK 8644, a
dihydropyridine derivative that binds to L-type calcium chan-
nels inducing a calcium in£ux, results in pro-IL-18 secretion;
in turn, pre-exposure of DCs to the calcium channel blocker
NFD inhibits the release of pro-IL-18 induced by T cells.
These data con¢rm the presence of functional L-type calcium
channels on DCs [18] and provide the evidence of an addi-
tional DC function, namely IL-18 secretion, mediated by the
activation of these structures. This novel mechanism of secre-
tion for IL-18, involving regulated exocytosis of secretory en-
dolysosomes, allows an early secretion of this cytokine by
DCs during the secondary immune response, which can pro-
vide a ¢rst warning to the immune system of the presence of
potentially dangerous pathogens. The rapid shut-down of in-
tracellular IL-18 after interaction with speci¢c T cells might
represent a mechanism of negative feed back aimed to focus
the early phases of the response on antigen speci¢c lympho-
cytes, preventing an uncontrolled ampli¢cation of the immune
reaction.
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